newsfilter
← Latest News
PR Newswire·

VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France

VNRX
  • VolitionRx Limited, a multi-national epigenetics company, officially launched the DETECSEPS project in France to improve the early detection of sepsis.
  • The government-funded consortium received €6.3 million (~$7.3 million) as part of the France 2030 plan to evaluate a new diagnostic strategy.
  • The program aims to identify patients with suspected infections upon Emergency Department arrival who are at risk of sepsis, allowing for earlier care or safe redirection home.
  • The strategy combines the National Early Warning Score (NEWS) 2 clinical assessment with Volition's Nu.Q® NETs H3.1 blood biomarker to quantify NETosis.
  • IDS France will provide the i10 automated analyzer to process the biomarker for quick results.
  • The study will evaluate this approach in 1,000 patients across real-life care settings at AP-HP hospitals (Bichat-Claude-Bernard, Ambroise Paré) and Hospices Civils de Lyon.
  • Volition is providing the Nu.Q® H3.1 Assay pro-bono for the duration of this evaluation.
  • If results are conclusive, the project aims to speed up care for at-risk patients, reduce unnecessary hospitalizations, and lower socio-economic costs.
  • The consortium includes industrial partners Volition and IDS France alongside academic institutions IHU Sepsis, AP-HP, and Hospices Civils de Lyon.
  • Sepsis is estimated to cause 21 million deaths annually worldwide, making rapid detection crucial for reducing mortality.